Product: c-PLA2 Antibody
Catalog: AF6329
Description: Rabbit polyclonal antibody to c-PLA2
Application: WB IHC IF/ICC
Reactivity: Human, Mouse, Rat
Prediction: Bovine, Horse, Sheep, Rabbit, Dog, Xenopus
Mol.Wt.: 110kDa; 85kD(Calculated).
Uniprot: P47712
RRID: AB_2835185

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Bovine(82%), Horse(82%), Sheep(82%), Rabbit(91%), Dog(82%), Xenopus(90%)
c-PLA2 Antibody detects endogenous levels of total c-PLA2.
Cite Format: Affinity Biosciences Cat# AF6329, RRID:AB_2835185.
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.


Calcium dependent phospholipid binding protein; CPLA 2; cPLA2 alpha; cPLA2; Cytosolic phospholipase A2; Cytosolic phospholipase A2 group IVA; Lysophospholipase; MGC126350; PA24A_HUMAN; Phosphatidylcholine 2 acylhydrolase; Phosphatidylcholine 2-acylhydrolase; Phospholipase A2 group 4 A; Phospholipase A2 group IVA (cytosolic calcium dependent); Phospholipase A2 group IVA; PhospholipaseA2; PLA2G4; pla2g4a;


P47712 PA24A_HUMAN:

Expressed in various tissues such as macrophages, neutrophils, fibroblasts and lung endothelium. Expressed in platelets (at protein level) (PubMed:25102815).

cPLA2 a calcium-dependent phospholipase A2 that catalyzes the release of arachidonic acid from membrane phospholipids. Selectively hydrolyzes arachidonyl phospholipids in the sn-2 position releasing arachidonic acid.



Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P47712 As Substrate

Site PTM Type Enzyme
S2 Phosphorylation
Y7 Phosphorylation
T21 Phosphorylation
T31 Phosphorylation
K32 Ubiquitination
C151 S-Nitrosylation
K155 Ubiquitination
T156 Phosphorylation
K171 Acetylation
K176 Acetylation
K176 Ubiquitination
S178 Phosphorylation
S183 Phosphorylation
S228 Phosphorylation
K257 Ubiquitination
T268 Phosphorylation
K271 Ubiquitination
K273 Ubiquitination
K281 Ubiquitination
K283 Ubiquitination
K316 Ubiquitination
Y359 Phosphorylation
S370 Phosphorylation
K371 Ubiquitination
S431 Phosphorylation
S434 Phosphorylation
S435 Phosphorylation
S437 Phosphorylation
S441 Phosphorylation
T447 Phosphorylation
S454 Phosphorylation
Y456 Phosphorylation
S458 Phosphorylation
S463 Phosphorylation
S505 Phosphorylation Q16539 (MAPK14) , P27361 (MAPK3) , P28482 (MAPK1)
S508 Phosphorylation
T512 Phosphorylation
S515 Phosphorylation
Y535 Phosphorylation
K541 Sumoylation
K541 Ubiquitination
K595 Ubiquitination
K606 Ubiquitination
K618 Ubiquitination
K691 Ubiquitination
S724 Phosphorylation
S727 Phosphorylation O75582 (RPS6KA5) , Q8IW41 (MAPKAPK5) , Q9BUB5 (MKNK1)
S729 Phosphorylation
S731 Phosphorylation
K741 Ubiquitination

Research Backgrounds


Selectively hydrolyzes arachidonyl phospholipids in the sn-2 position releasing arachidonic acid. Together with its lysophospholipid activity, it is implicated in the initiation of the inflammatory response.


Activated by phosphorylation at both Ser-505 and Ser-727.

Subcellular Location:

Cytoplasm. Cytoplasmic vesicle.
Note: Translocates to membrane vesicles in a calcium-dependent fashion.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed in various tissues such as macrophages, neutrophils, fibroblasts and lung endothelium. Expressed in platelets (at protein level).

Subunit Structure:

Interacts with KAT5.


The N-terminal C2 domain associates with lipid membranes upon calcium binding. It modulates enzyme activity by presenting the active site to its substrate in response to elevations of cytosolic Ca(2+).

Research Fields

· Cellular Processes > Cell growth and death > Necroptosis.   (View pathway)

· Environmental Information Processing > Signal transduction > MAPK signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Ras signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Phospholipase D signaling pathway.   (View pathway)

· Human Diseases > Cancers: Overview > Choline metabolism in cancer.   (View pathway)

· Metabolism > Lipid metabolism > Glycerophospholipid metabolism.

· Metabolism > Lipid metabolism > Ether lipid metabolism.

· Metabolism > Lipid metabolism > Arachidonic acid metabolism.

· Metabolism > Lipid metabolism > Linoleic acid metabolism.

· Metabolism > Lipid metabolism > alpha-Linolenic acid metabolism.

· Metabolism > Global and overview maps > Metabolic pathways.

· Organismal Systems > Circulatory system > Vascular smooth muscle contraction.   (View pathway)

· Organismal Systems > Immune system > Platelet activation.   (View pathway)

· Organismal Systems > Immune system > Fc epsilon RI signaling pathway.   (View pathway)

· Organismal Systems > Immune system > Fc gamma R-mediated phagocytosis.   (View pathway)

· Organismal Systems > Nervous system > Glutamatergic synapse.

· Organismal Systems > Nervous system > Serotonergic synapse.

· Organismal Systems > Nervous system > Long-term depression.

· Organismal Systems > Sensory system > Inflammatory mediator regulation of TRP channels.   (View pathway)

· Organismal Systems > Endocrine system > Ovarian steroidogenesis.

· Organismal Systems > Endocrine system > Oxytocin signaling pathway.


1). Identification of a natural PLA2 inhibitor from the marine fungus Aspergillus sp. c1 for MAFLD treatment that suppressed lipotoxicity by inhibiting the IRE-1α/XBP-1s axis and JNK signaling. Acta Pharmaceutica Sinica B, 2023 (PubMed: 38261820) [IF=14.5]

Application: WB    Species: Human    Sample:

Figure 6 PLA2 is supposed to be an upstream regulator of ER stress and lipotoxicity. (A) Proposed mechanism by which PLA2 regulates ER stress and hepatocyte death. (B‒C) Determination of cellular PLA2 enzyme activity and LPC levels. (D) Protein levels of the PLA2 and JNK pathways. (E) Immunofluorescence analysis of protein PLA2. Scale bar, 50 μm. (F–G) Time-dependent effects of HN-001 in suppressing PLA2 activity (F) and the PLA2/JNK axis (G). (H–M) Hepatocytes were treated with the PLA2 inhibitor MAFP (3 μmol/L) for 24 h in the presence or absence of PA, and then cells were harvested and subjected to the indicated examinations. (H) Cellular PLA2 enzyme activity. (I) Cellular LPC level. (J) mRNA level of Xbp-1s. (K) ROS level. (L) Caspase 3 activity determination. (M) Viable cell counting. n = 5 independent experiments. (N) Molecular docking analysis between HN-001 and the protein PLA2. The crystal structure of human PLA2 (PDB ID: 1BCI) was selected. The hydrogen bond and hydrophobic force are displayed as blue and yellow dashed lines, respectively. The image was generated in PyMOL. (O) Determination of the binding affinity of HN-001 for the protein PLA2. (P) PLA2 enzyme activity determination. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, compared with blank group (PA-untreated) cells; #P < 0.05, ##P < 0.01, ###P < 0.001, compared with PA-treated cells.

2). p47phox deficiency impairs platelet function and protects mice against arterial and venous thrombosis. Redox Biology, 2020 (PubMed: 32422541) [IF=11.4]

Application: WB    Species: Human    Sample: platelets

Fig. 4. ROS generation and phosphorylation of VASP, ERK1/2, p38 MAPK, ERK5, JNK, AKT and c-PLA2. (A) Western blot analysis of the expression of NOX2, p67phox, NOX1, NOXO1 and Rac in WT and p47phox-/- platelets. (B) ROS generation in platelets after stimulation with CRP (2 μg/ml) or thrombin (0.5 U/ml) was expressed as mean fluorescent intensity (MFI) (mean ± SE, n = 6) (Student t-test). (C) The phosphorylation level of VASP, ERK1/2, p38, ERK5 and JNK in CRPstimulated platelets was detected by western blot and (D) quantified as a ratio relative to the total level (mean ± SD, n = 3) (Two-way ANOVA). (E) The phosphorylation level of AKT and c-PLA2 was also detected and (F) quantified (mean ± SD, n = 3) (Two-way ANOVA). *p < 0.05; **p < 0.01; ***p < 0.001.

3). The ERK-cPLA2-ACSL4 axis mediating M2 macrophages ferroptosis impedes mucosal healing in ulcerative colitis. Free radical biology & medicine, 2024 (PubMed: 38367927) [IF=7.4]

4). Fexofenadine protects against lipopolysaccharide-induced acute lung injury by targeting cytosolic phospholipase A2. International Immunopharmacology, 2023 (PubMed: 36764283) [IF=5.6]

5). Inhibitory effect of tumor necrosis factor‑α on the basolateral Kir4. 1/Kir5. 1 channels in the thick ascending limb during diabetes. Experimental and Therapeutic Medicine, 2021 (PubMed: 34539838) [IF=2.7]

Application: WB    Species: Rat    Sample:

Figure 3 Change in protein expression of PLA2 in the thick ascending limb during diabetes. **P<0.01 vs. control group; #P<0.05 vs. diabetic group. TNFR:Fc, TNF receptor fusion protein; PLA2, phospholipase A2.

6). NOX4/Src regulates ANP secretion through activating ERK1/2 and Akt/GATA4 signaling in beating rat hypoxic atria. KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY, 2021 (PubMed: 33602886) [IF=2.0]

Application: WB    Species: Rat    Sample: hypoxic beating rat atria

Fig. 3 Effects of ETR and PLA2 antagonists on NOX4 (A, B & D) and pcPLA2 (C) expression in beating rat atria under normoxic conditions. Data were expressed as the mean ± standard error of the mean (n = 5). Cont, control; ET, ET-1; Var, varespladib, an antagonist of sPLA2; CAY, CAY10650, an antagonist of cPLA2. *p < 0.05 vs. control; &p < 0.05 vs. ET-1.

7). Cholecystokinin Octapeptide Promotes ANP Secretion through Activation of NOX4–PGC-1α–PPARα/PPARγ Signaling in Isolated Beating Rat Atria. Oxidative Medicine and Cellular Longevity, 2022 (PubMed: 35770043)

Restrictive clause


Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.